Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 12
1986 65
1987 189
1988 168
1989 352
1990 306
1991 244
1992 241
1993 225
1994 173
1995 218
1996 178
1997 183
1998 173
1999 178
2000 158
2001 175
2002 179
2003 222
2004 274
2005 287
2006 325
2007 264
2008 282
2009 261
2010 254
2011 291
2012 301
2013 286
2014 326
2015 357
2016 319
2017 294
2018 305
2019 146
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

7,719 results
Results by year
Filters applied: . Clear all
Page 1
Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?
Bidell MR and Lodise TP. Pharmacotherapy 2016 - Review. PMID 27138564
Fluoroquinolone antibiotics recently have gained increased national attention due to safety concerns. A well-described and serious adverse event associated with receipt of fluoroquinolones is tendinitis and tendon rupture. ...Given widespread use of levofloxacin across patient care settings, knowledge of both patient- and drug-specific characteristics associated with increased risk of tendinitis and tendon rupture can promote safe use of levofloxacin and other fluoroquinolones....
Fluoroquinolone antibiotics recently have gained increased national attention due to safety concerns. A well-described and serious ad
Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals.
Martinez M, et al. Vet J 2006 - Review. PMID 16154368
The first of the fluoroquinolones approved for use in animals, enrofloxacin, was approved in the late 1980s. Since then, five other fluoroquinolones have been marketed for use in animals in the United States, with others currently under investigation. This review focuses on the use of fluoroquinolones within veterinary medicine, providing an overview of the structure-activity relationship of the various members of the group, the clinical uses of fluoroquinolones in veterinary medicine, their pharmacokinetics and potential interspecies differences, an overview of the current understanding of the pharmacokinetic/pharmacodynamic relationships associated with fluoroquinolones, a summary of toxicities that have been associated with this class of compounds, their use in both in human and veterinary species, mechanisms associated with the development of microbial resistance to the fluoroquinolones, and a discussion of fluoroquinolone dose optimization. ...
The first of the fluoroquinolones approved for use in animals, enrofloxacin, was approved in the late 1980s. Since then, five …
The use of fluoroquinolones in the treatment of skin infections.
Martin SJ and Zeigler DG. Expert Opin Pharmacother 2004 - Review. PMID 14996621
However, resistance to the fluoroquinolones has increased among the staphylococci, streptococci, Enterobacteriaceae and other important Gram-negative bacilli. Resistance has been linked directly to the widespread use of these compounds. Despite their appeal in the treatment of both uncomplicated and complicated skin infections, the fluoroquinolones should be reserved as alternatives to beta-lactams and other antibiotics or as empirical therapy in complicated infections until pathogens have been identified and drug regimens can be focused....
However, resistance to the fluoroquinolones has increased among the staphylococci, streptococci, Enterobacteriaceae and other importa …
The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
Thabet L, et al. Tunis Med 2010. PMID 20517823 Free article.
The use of fluoroquinolones was correlated significantly with MRSA (rs=0.96, P<0.05) . The restriction use of FQ was significantly associated with a decrease of MRSA. ...However, there is not a correlation (P> 0.05) between fluoroquinolones use and resistance in A. baumannii as well in ciprofloxacin, imipenem and ceftazidime. ...
The use of fluoroquinolones was correlated significantly with MRSA (rs=0.96, P<0.05) . The restriction use of FQ was …
The use of fluoroquinolones in children: recent advances.
Velissariou IM. Expert Rev Anti Infect Ther 2006 - Review. PMID 17140360
Their use in children, however, has been limited until recently as a result of possible fluoroquinolone-induced joint toxicity. Nevertheless, this group of antibiotics is rapidly gaining consideration for use in children as new agents are emerging with a wide antimicrobial range of action and minimal toxicity, even in young children. ...
Their use in children, however, has been limited until recently as a result of possible fluoroquinolone-induced joint toxicity …
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency
Bennett AC, et al. Expert Opin Drug Saf 2019 - Review. PMID 31500468
Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the most commonly prescribed antibiotics. ...
Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the mo …
The use of systemic fluoroquinolones.
Committee on Infectious Diseases . Pediatrics 2006. PMID 16951028
The increased use of fluoroquinolones in adults has resulted in increased bacterial resistance to this class of antibacterial agents. This report provides specific guidelines for the systemic use of fluoroquinolones in children. Fluoroquinolone use should be restricted to situations in which there is no safe and effective alternative to treat an infection caused by multidrug-resistant bacteria or to provide oral therapy when parenteral therapy is not feasible and no other effective oral agent is available....
The increased use of fluoroquinolones in adults has resulted in increased bacterial resistance to this class of antibacterial …
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis
Xu J and Feng J. Pak J Pharm Sci 2018 - Clinical Trial. PMID 30203775
It not only maintains the antibacterial effect of the three generation of fluoroquinolones on Gram-negative bacteria, but also enhances the effectiveness of gatifloxacin, including other Gram-positive bacteria and anaerobes. ...
It not only maintains the antibacterial effect of the three generation of fluoroquinolones on Gram-negative bacteria, but also enhanc …
7,719 results
Jump to page
Feedback